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Abstract
Predicting crystallographic B-factors of a protein from a conventional molecular
dynamics simulation is challenging, in part because the B-factors calculated
through sampling the atomic positional fluctuations in a picosecond molecular
dynamics simulation are unreliable, and the sampling of a longer simulation yields
overly large root mean square deviations between calculated and experimental
B-factors. This article reports improved B-factor prediction achieved by sampling
the atomic positional fluctuations in multiple picosecond molecular dynamics
simulations that use uniformly increased atomic masses by 100-fold to increase
time resolution. Using the third immunoglobulin-binding domain of protein G,
bovine pancreatic trypsin inhibitor, ubiquitin, and lysozyme as model systems, the
B-factor root mean square deviations (mean ± standard error) of these proteins
were 3.1 ± 0.2–9 ± 1 Å2 for Cα and 7.3 ± 0.9–9.6 ± 0.2 Å2 for Cγ, when the
sampling was done for each of these proteins over 20 distinct, independent, and
50-picosecond high-mass molecular dynamics simulations with AMBER forcefield
FF12MC or FF14SB. These results suggest that sampling the atomic positional
fluctuations in multiple picosecond high-mass molecular dynamics simulations
may be conducive to a priori prediction of crystallographic B-factors of a folded
globular protein.
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1. Introduction
The B-factor (also known as the Debye-Waller factor or B-value) of a given atom
in a crystal structure is defined as 8 π2 〈 u2〉 that is used in refining the crystal
structure to reflect the displacement u of the atom from its mean position in the
crystal structure (viz., the uncertainty of the atomic mean position) [1, 2, 3, 4, 5, 6,
7, 8, 9, 10]. The displacement u attenuates X-ray scattering and is caused by the
thermal motion, conformational disorder, and static lattice disorder of the atom [6].
It is worth noting that the experimentally determined B-factor is not a quantity that
is directly observed from an experiment. Instead, it is a function that not only
decreases as the resolution of the crystal structure increases [10], but also depends
on the restraints that are applied on B-factors in refining the crystal structure [4, 8].
B-factors can be unrealistic if excessive refinement is performed to achieve a
higher resolution. B-factors of one crystal structure cannot be compared to those of
another without detailed knowledge of the refinement processes for the two
comparing structures. It is also worthy of noting that the Subcommittee on Atomic
Displacement Parameter Nomenclature recommends avoiding referring to B-factor
as “temperature factor” in part because the displacement may not be caused
entirely by the thermal motion [7].
Despite the complex nature of B-factor and challenges of separating the thermal
motion in time from the conformational and static lattice disorders in space [11],
B-factors of a protein crystal structure can be used to quantitatively identify less
mobile regions of a crystal structure as long as the structure is determined without
substantial crystal lattice defects, rigid-body motions, and refinement errors [8, 12,
13]. A low B-factor indicates low thermal motion, and a high B-factor may imply
high thermal motion. Normalized main-chain B-factors of a protein have been used
as an estimator of flexibility for each residue of the protein [14, 15, 16, 17, 18, 19]
to offer useful information for drug-target identification. Unscaled main-chain and
side-chain B-factors of a protein can be used to identify ordered regions of a folded
globular protein and relatively rigid side chains of active-site residues for target-
structure–based drug design [20, 21]. Other uses of B-factors are outlined in Ref.
[22].
As of August 2016, there are more than 65 million protein sequences at the
Universal Protein Resource (http://www.uniprot.org/statistics/TrEMBL) compared
to about 106 thousand protein crystal structures available at the Protein Data Bank
(http://www.rcsb.org/pdb/statistics/holdings.do). This difference indicates that one
can use crystallographic methods to determine structures and B-factors of only a
fraction of known protein sequences. Most known protein sequences will have to
be used for target identification and drug design through generation and refinement
Article No~e00161
2 http://dx.doi.org/10.1016/j.heliyon.2016.e00161
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
of comparative or homology models from the protein sequences [23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]. Currently,
knowledge-based methods can predict main-chain B-factor distribution of a protein
from either its sequence using statistical methods [15, 17, 18, 19, 43, 44, 45, 46] or
its structure using a single-parameter harmonic potential [47, 48] with Pearson
correlation coefficients (PCCs) up to 0.71 for the predicted B-factors relative to the
experimental values. These methods do not require intense computation and can
rapidly predict B-factors of large numbers of protein sequences to facilitate the use
of these sequences in drug-target identification. However, target-structure–based
drug design requires more detailed B-factor information than drug-target
identification. To design drug candidates whose binding to their protein targets
is both enthalpy- and entropy-driven, one needs the information on side-chain
motions of active-site residues in a protein target. Prediction of side-chain
B-factors by the knowledge-based methods has not been reported to date and may
not be feasible through the use of a single-parameter harmonic potential that is
inapplicable to high frequency modes pertaining to rapid oscillations of some
amino acid side chains [49].
To complement the current knowledge-based methods, there is a need to develop
physics-based methods for predicting unscaled B-factors of both main-chain and
side-chain atoms of a protein crystal structure or a refined comparative protein
model from molecular dynamics (MD) simulation. By solving the Newtonian
equations of motion for all atoms in a molecular system as a function of time, MD
simulation is a general method to simulate atomic motions of the system for
insights into dynamical properties of the system such as transport coefficients,
time-dependent response to perturbations, rheological properties, and spectra [50].
However, predicting B-factors of a folded globular protein by sampling the atomic
positional fluctuations of a protein in a conventional MD simulation with solvation
may not be feasible because of the use of different protein environments, different
timescales to detect thermal motions, and different methods to determine B-factors
[51]. For example, a reported MD simulation study showed that the B-factors
derived on the picosecond timescale were unreliable, and that the simulated
B-factors on the nanosecond timescale were considerably larger than the
experimental values [51]. Although simulations of proteins in their crystalline
state [52, 53] can avoid the difference in protein environment, such simulations are
inapplicable to a priori B-factor prediction.
This article reports an evaluation study of a physics-based method that samples the
atomic positional fluctuations in 20 distinct, independent, unrestricted, unbiased,
picosecond, and classical isobaric–isothermal (NPT) MD simulations with
uniformly scaled atomic masses to predict a priori main-chain and side-chain
B-factors of a folded globular protein for target-structure–based drug design. The
model systems of folded globular proteins used in this study were the third
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immunoglobulin-binding domain of protein G (GB3; PDB ID: 1IGD; resolution:
1.10 Å) [54], bovine pancreatic trypsin inhibitor (BPTI; PDB ID: 4PTI; resolution:
1.50 Å) [55], ubiquitin (PDB ID: 1UBQ; resolution: 1.80 Å) [56], and lysozyme
(PDB ID: 4LZT; resolution: 0.95 Å) [57]. Two distinct AMBER forcefields,
FF12MC [42, 58, 59, 60] and FF14SB [61], were used to evaluate the method in a
forcefield-independent manner. The root mean square deviations (RMSDs) and
PCCs between the experimental B-factors and the predicted values by the physics-
based method were compared respectively to the estimated standard error of the
experimental B-factors derived from the refinement procedure [8] and to the PCCs
of the reported knowledge-based methods [46, 47] in order to assess the quality of
the B-factors predicted by the physics-based method. Unless otherwise specified
below, all B-factors are unscaled, and all simulations are multiple, distinct,
independent, unrestricted, unbiased, and classical NPT MD simulations.
2. Theory
2.1. Using uniformly reduced atomic masses to compress the MD
simulation time
Reducing atomic masses of the entire simulation system (including both solute and
solvent) uniformly by tenfold—hereafter referred to as low masses—can enhance
configurational sampling in NPT MD simulations [62]. The effectiveness of the
low-mass NPT MD simulation technique can be explained as follows: To
determine the relative configurational sampling efficiencies of two simulations of
the same system, one with standard masses and another with low masses, the units
of distance [l] and energy [m]([l]/[t])2 of the low-mass simulation are kept identical
to those of the standard-mass simulation, noting that energy and temperature have
the same unit. This is so that the structure and energy of the low-mass simulation
system can be compared to those of the standard-mass simulation system. Let
superscripts lmt and smt denote the times for the low-mass and standard-mass
systems, respectively. Then [mlmt] = 0.1 [msmt], [llmt] = [lsmt], and [mlmt]([llmt]/
[tlmt])2 = [msmt]([lsmt]/[tsmt])2 lead to
ﬃﬃﬃﬃﬃ
10
p
[tlmt] = [tsmt]. A conventional MD
simulation program takes the timestep size (Δt) of the standard-mass time rather
than that of the low-mass time. Therefore, low-mass MD simulations at Δt =
1.00 fssmt (viz.,
ﬃﬃﬃﬃﬃ
10
p
fslmt) are theoretically equivalent to standard-mass MD
simulations at Δt =
ﬃﬃﬃﬃﬃ
10
p
fssmt, as long as both standard-mass and low-mass
simulations are carried out for the same number of timesteps and there are no
precision issues in performing these simulations. This equivalence of mass
downscaling and timestep-size upscaling explains why uniform mass reduction
can compress the MD simulation time and why low-mass NPT MD simulations
at Δt = 1.00 fssmt can offer better configurational sampling efficacy than
conventional standard-mass NPT MD simulations at Δt = 1.00 fssmt or Δt = 2.00
fssmt. It also clarifies why the kinetics of the low-mass simulation system can be
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converted to the kinetics of the standard-mass simulation system simply by
scaling the low-mass time with a factor of
ﬃﬃﬃﬃﬃ
10
p
[60]. Further, this equivalence
explains there are limitations on the use of the mass reduction technique to
improve configurational sampling efficiency. Lengthening the timestep size
inevitably reduces integration accuracy of an MD simulation. However, the
integration accuracy reduction caused by a timestep-size increase is temperature
dependent. Therefore, to avoid serious integration errors, low-mass NPT MD
simulations must be performed with the double-precision floating-point format
and at Δt ≤1.00 fssmt and a temperature of ≤340 K [60]. Because temperatures of
biological systems rarely exceed 340 K, and because MD simulations are
performed typically with the double-precision floating-point format, low-mass
NPT MD simulation is a viable configurational sampling enhancement technique
for protein simulations at a temperature of ≤340 K. In this context, to efficiently
sample alternative conformations from a crystallographically determined
conformation, low-mass NPT MD simulations at Δt = 1.00 fssmt and temperature
of <340 K were used for GB3, BPTI, ubiquitin, and lysozyme in this study.
2.2. Using uniformly increased atomic masses to expand the MD
simulation time
In the same vein, let superscript hmt denote the time for the system with uniformly
increased atomic masses by 100-fold (hereafter referred to as high masses), then
[mhmt] = 100 [msmt], [lhmt] = [lsmt], and [mhmt]([lhmt]/[thmt])2 = [msmt]([lsmt]/[tsmt])2
lead to [thmt] = 10 [tsmt]. This equivalence of mass upscaling and timestep-size
downscaling explains why uniform mass increase can expand the MD simulation
time and why high-mass NPT MD simulations at Δt = 1.00 fssmt can increase their
time resolution by tenfold. Therefore, to adequately sample the atomic positional
fluctuations in a short simulation, high-mass NPT MD simulations at Δt = 1.00
fssmt were used for GB3, BPTI, ubiquitin, and lysozyme in the present study.
Although standard-mass simulations at Δt = 0.10 fssmt can achieve the same time
resolution, the high-mass simulation with Δt = 1.00 fssmt has an advantage in that,
through modifying the atomic masses specified in a forcefield parameter file rather
than the source code of the simulation package, one can simulate a guest•host
complex with the compressed and expanded simulation times respectively applied
to the guest and the host, or a homology model of a protein with the compressed
and expanded simulation times respectively applied to the active-site region and
the rest of the protein. The simulation time resolution can also be increased by
sampling conformations saved at every 50 timesteps of a standard-mass simulation
at Δt = 1.00 fssmt [4, 51] rather than sampling conformations saved at every 103
timesteps of a high-mass simulation as described in Section 3.2. However, to
simultaneously perform 20 simulations of a large protein with explicit solvation,
the high-mass simulations are preferred over the standard-mass simulations
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because simultaneously saving 20 large files of the coordinates of the protein with
a vast number of water molecules at every 50 timesteps is more computationally
expensive than at every 103 timesteps.
3. Methods
3.1. MD simulations of folded globular proteins
A folded globular protein was solvated with the TIP3P water [63] with surrounding
counter ions and then energy-minimized for 100 cycles of steepest-descent
minimization followed by 900 cycles of conjugate-gradient minimization to
remove close van der Waals contacts using SANDER of AMBER 11 (University
of California, San Francisco). The resulting system was heated—in 20 distinct,
independent, unrestricted, unbiased, and classical MD simulations with a periodic
boundary condition and unique seed numbers for initial velocities—from 0 to 295
or 297 K at a rate of 10 K/ps under constant temperature and constant volume, then
equilibrated with a periodic boundary condition for 106 timesteps under constant
temperature and constant pressure of 1 atm employing isotropic molecule-based
scaling, and lastly simulated under the NPT condition at 1 atm and a constant
temperature of 295 K or 297 K using PMEMD of AMBER 11.
The initial conformations of GB3, BPTI, ubiquitin, and lysozyme for the simulations
were taken from the crystal structures of PDB IDs of 1IGD, 5PTI, 1UBQ, and 4LZT,
respectively. A truncated 1IGD structure (residues 6–61) was used for the GB3
simulations. Four interior water molecules (WAT111, WAT112, WAT113, and
WAT122) were included in the initial 5PTI conformation. The simulations for GB3,
BPTI, and ubiquitin were done at 297 K as the exact data-collection temperatures of
these proteins had not been reported. The lysozyme simulations were done at the
reported data-collection temperature of 295 K [57].
The numbers of TIP3P waters and surrounding ions, initial solvation box size, and
protonation states of ionizable residues used for the NPT MD simulations are
provided in Table 1. The 20 unique seed numbers for initial velocities of
Table 1. Numbers of TIP3P waters and ions, initial solvation box size, and protonation state of ionizable
residue used in molecular dynamics simulations.
Sequence # of H2O # of Na
+ # of Cl− Box size (Å3) Expt pH Protonation State of
Ionizable Residue
GB3 2528 2 0 45 × 57 × 47 5.8 ASP,GLU,LYS
BPTI 3108 0 6 49 × 47 × 62 4.6 ARG,ASP,GLU,LYS
Ubiquitin 3881 0 1 50 × 66 × 53 4.7 ARG,ASP,GLU,LYS,HIP
Lysozyme 5849 0 12 60 × 61 × 69 3.8 ARG,ASP,ASH101,GLH,LYS,HIP
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Simulations 1–20 were taken from Ref. [58]. All simulations used (i) a dielectric
constant of 1.0, (ii) the Berendsen coupling algorithm [64], (iii) the Particle Mesh
Ewald method to calculate electrostatic interactions of two atoms at a separation of
>8 Å [65], (iv) Δt = 1.00 fssmt, (v) the SHAKE-bond-length constraints applied to
all bonds involving hydrogen, (vi) a protocol to save the image closest to the
middle of the “primary box” to the restart and trajectory files, (vii) a formatted
restart file, (viii) the revised alkali and halide ions parameters [66], (ix) a cutoff of
8.0 Å for nonbonded interactions, (x) the atomic masses of the entire simulation
system (including both solute and solvent) that were uniformly increased by
100-fold or decreased by tenfold relative to the standard atomic masses, and (xi)
default values of all other inputs of the PMEMD module. The forcefield parameters
[(Fig._1)TD$FIG]
Fig. 1. Experimental and calculated B-factors of GB3, BPTI, ubiquitin, and lysozyme. The B-factors
were calculated from 20 50-pssmt high-mass molecular dynamics simulations using FF12MChm or
FF14SBhm. The letter “r” is the abbreviation for the Pearson correlation coefficient.
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of FF12MC are available in the Supporting Information of Ref. [60]. All
simulations were performed on a cluster of 100 12-core Apple Mac Pros with Intel
Westmere (2.40/2.93 GHz).
3.2. Crystallographic B-factor prediction
Using a two-step procedure with PTRAJ of AmberTools 1.5, the B-factors of Cα
and Cγ atoms in a folded globular protein were predicted from all conformations
saved at every 103 timesteps of 20 simulations of the protein using the simulation
conditions described above. The first step was to align all saved conformations
onto the first saved one to obtain an average conformation using root mean square
fit of all CA atoms (for Cα B-factors) or all CG and CG2 atoms (for Cγ B-factors).
The second step was to root mean square fit all CA atoms (or all CG and CG2
atoms) in all saved conformations onto the corresponding atoms of the average
conformation, and then calculate the Cα (or Cγ) B-factors using the “atomicfluct”
command in PTRAJ. For each protein, the calculated B-factor of an atom in Fig. 1
and Table S1 of Supplementary Content was the mean of all B-factors of the atom
derived from 20 simulations of the protein. The standard error (SE) of a B-factor
was calculated according to Eq. 2 of Ref. [59]. The SE of an RMSD between
computed and experimental B-factors was calculated using the same method for
the SE of a B-factor. The experimental B-factors of GB3, BPTI, ubiquitin, and
lysozyme were taken from the crystal structures of PDB IDs of 1IGD, 4PTI,
1UBQ, and 4LZT, respectively.
3.3. Correlation analysis
PCCs were obtained from correlation analysis using PRISM 5 for Mac OS X of
GraphPad Software (La Jolla, California) with the assumption that data were
sampled from Gaussian populations.
4. Results and discussion
4.1. Using high–time-resolution picosecond MD simulations to
calculate B-factors
The internal motions—such as the motions of backbone N–H bonds of a folded
globular protein at the solution state—are on the order of tens or hundreds of pssmt
[67]. Therefore, the timescale of the thermal motions reflected in the B-factors of a
protein at the crystalline state is unlikely greater than a nanosecond. As described
in Section 1, the B-factor of a given atom reflects both the thermal motion and the
conformation and static lattice disorders of the atom [6]. In this context, 20 high-
mass MD simulations of a folded globular protein were carried out to investigate
whether combining the sampling of the atomic positional fluctuations of the protein
on a timescale of tens or hundreds of pssmt with the sampling of such fluctuations
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Table 2. Root mean square deviations between experimental and calculated
B-factors of GB3, BPTI, ubiquitin, and lysozyme.
Protein
(temperature)
Time
(pssmt)
RMSD (mean ± SE in Å2)
Cα Cγ
FF12MChm FF14SBhm FF12MChm FF14SBhm
Ubiquitin (297 K) 25 6.2 ± 0.3 7.1 ± 0.2 7.0 ± 0.9 9.3 ± 0.2
50 9 ± 1 8.2 ± 0.6 7.3 ± 0.9 8.4 ± 0.3
100 16 ± 2 12 ± 1 12 ± 1 7.8 ± 0.6
200 32 ± 3 21 ± 2 20 ± 2 9 ± 1
300 37 ± 4 28 ± 3 25 ± 3 10 ± 1
400 40 ± 4 32 ± 3 27 ± 3 11 ± 1
500 43 ± 4 36 ± 3 29 ± 3 12 ± 2
BPTI (297 K) 25 5.9 ± 0.3 6.8 ± 0.3 8.6 ± 0.4 10.7 ± 0.2
50 4.8 ± 0.6 6.1 ± 0.6 8.7 ± 0.6 9.6 ± 0.2
100 5.2 ± 0.8 7.3 ± 0.9 11 ± 1 9.1 ± 0.3
200 8 ± 1 10 ± 1 13 ± 1 8.8 ± 0.4
300 13 ± 2 14 ± 2 15 ± 1 8.8 ± 0.5
400 15 ± 2 16 ± 2 17 ± 1 8.9 ± 0.6
500 17 ± 2 18 ± 2 19 ± 1 8.9 ± 0.6
GB3 (297 K) 25 3.7 ± 0.1 4.2 ± 0.1 9.3 ± 0.5 10.3 ± 0.2
50 3.1 ± 0.2 3.6 ± 0.1 9.2 ± 0.8 9.4 ± 0.3
100 3.7 ± 0.7 3.4 ± 0.2 12 ± 2 8.8 ± 0.6
200 5.3 ± 0.9 3.3 ± 0.2 17 ± 2 8.4 ± 0.7
300 5.9 ± 0.8 3.2 ± 0.2 19 ± 2 8.0 ± 0.6
400 8 ± 1 3.3 ± 0.2 23 ± 2 8.4 ± 0.6
500 9 ± 1 3.6 ± 0.3 25 ± 2 9.5 ± 0.9
600 9 ± 1 4.0 ± 0.5 26 ± 2 11 ± 1
700 10 ± 1 4.3 ± 0.5 27 ± 2 12 ± 1
800 10 ± 1 4.6 ± 0.6 28 ± 2 12 ± 1
900 10 ± 1 4.9 ± 0.7 28 ± 2 13 ± 2
1000 10 ± 1 5.2 ± 0.7 29 ± 2 13 ± 2
Lysozyme (295 K) 25 5.2 ± 0.3 6.7 ± 0.1 7.4 ± 0.5 9.5 ± 0.1
50 4.2 ± 0.4 6.0 ± 0.1 7.7 ± 0.7 8.8 ± 0.2
100 3.5 ± 0.6 5.5 ± 0.1 10 ± 1 8.4 ± 0.2
200 4.0 ± 0.6 5.1 ± 0.1 13 ± 1 8.3 ± 0.3
300 5.2 ± 0.6 5.1 ± 0.1 17 ± 1 8.6 ± 0.4
400 6.9 ± 0.8 5.0 ± 0.1 20 ± 1 8.9 ± 0.4
500 8 ± 1 4.9 ± 0.1 22 ± 2 9.0 ± 0.4
600 9 ± 1 4.9 ± 0.1 24 ± 2 9.2 ± 0.4
(Continued)
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over conformations derived from the 20 simulations could approximate the
experimental B-factors. High-mass simulations were used to increase the time
resolution of the simulations and performed with FF12MChm or FF14SBhm,
which denote the AMBER forcefields FF12MC or FF14SB with all atomic masses
that were uniformly increased by 100-fold relative to the standard atomic masses.
Table 2. (Continued)
Protein
(temperature)
Time
(pssmt)
RMSD (mean ± SE in Å2)
Cα Cγ
FF12MChm FF14SBhm FF12MChm FF14SBhm
700 10 ± 1 4.9 ± 0.1 26 ± 3 9.4 ± 0.4
800 11 ± 2 4.8 ± 0.1 27 ± 3 9.5 ± 0.4
900 11 ± 2 4.8 ± 0.1 28 ± 3 9.6 ± 0.4
1000 12 ± 2 4.8 ± 0.1 29 ± 3 9.7 ± 0.4
10,000 — 4.7 ± 0.5 — 16 ± 1
20,000 — 5.4 ± 0.8 — 19 ± 2
Time: the duration of 20 distinct, independent, unrestricted, unbiased, and isobaric–isothermal
molecular dynamics simulations over which the B-factors were calculated. RMSD: root mean square
deviation. SE: standard error calculated from 20 distinct, independent, unrestricted, unbiased, and
isobaric–isothermal molecular dynamics simulations.
Table 3. Effects of the number of molecular dynamics simulations on the root
mean square deviation between experimental and calculated B-factors of ubiquitin.
Forcefield Time
(pssmt)
RMSD (mean ± SE in Å2)
Cα Cγ
N = 20 N = 40 N = 80 N = 20 N = 40 N = 80
25 6.2 ± 0.3 6.5 ± 0.3 6.7 ± 0.2 7.0 ± 0.9 7.0 ± 0.5 7.2 ± 0.3
FF12MChm 50 9 ± 1 9.2 ± 0.8 9.4 ± 0.6 7.3 ± 0.9 7.4 ± 0.6 7.2 ± 0.4
100 16 ± 2 15 ± 1 15.0 ± 0.8 12 ± 1 11.0 ± 0.8 10.5 ± 0.6
25 7.1 ± 0.2 7.3 ± 0.3 7.4 ± 0.3 9.3 ± 0.2 9.4 ± 0.1 9.3 ± 0.1
FF14SBhm 50 8.2 ± 0.6 8.3 ± 0.7 8.2 ± 0.5 8.4 ± 0.3 8.3 ± 0.2 8.2 ± 0.1
100 12 ± 1 11.0 ± 0.9 13 ± 1 7.8 ± 0.6 7.6 ± 0.4 7.5 ± 0.3
Time: the duration of N distinct, independent, unrestricted, unbiased, and isobaric–isothermal molecular
dynamics simulations over which the B-factors were calculated. RMSD: root mean square deviation.
SE: standard error calculated from N distinct, independent, unrestricted, unbiased, and isobaric-
–isothermal molecular dynamics simulations.
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As listed in Table 2, regardless of which forcefield was used, the RMSDs between
computed and experimental B-factors of Cα and Cγwere<10 Å2 for all four proteins
when the atomic positional fluctuations of these proteins were sampled on the
timescale of 50 pssmt. When FF12MChm was used, longer samplings led to the
RMSDs of ≥10 Å2 for all four proteins, and these RMSDs progressed in time
(Table 2). When FF14SBhm was used with longer samplings, the RMSDs were also
>10 Å2 for GB3, ubiquitin, and BPTI. For the lysozyme B-factors predicted with
FF14SBhm, the RMSDswere<10 Å2 when the sampling were done on the timescale
of<1 nssmt, but the RMSDs were >15 Å2 for the samplings on the timescale of 10 or
20 nssmt (Table 2). FF12MChm best reproduced most of the experimental B-factors
on the timescale of 50 pssmt with RMSDs (mean ± SE) ranging from 3.1± 0.2 to 9 ± 1
Å2 for Cα and from 7.3 ± 0.9 to 9.2 ± 0.8 Å2 for Cγ. FF14SBhm also best reproduced
most of the experimental B-factors on the timescale of 50 pssmt with RMSDs (mean ±
SE) from 3.6 ± 0.1 to 8.2 ± 0.6 Å2 for Cα and from 8.4 ± 0.3 to 9.6 ± 0.2 Å2 for Cγ.
Regardless of which forcefield was used, the means and SEs of the B-factor RMSDs
of ubiquitin were larger than those of the other proteins (Table 2). It was logical to
suspect that the conformational variations resulting from 20 simulations might be
insufficient to represent the conformational disorder of the ubiquitin crystals.
However, increasing the number of the ubiquitin simulations from 20 to 40 or 80
reduced the SEs but not the means (Table 3).
For all four proteins, the agreement of the calculated Cα and Cγ B-factors on the
timescale of 50 pssmt with the experimental values is shown in Fig. 1, and the SEs
of the predicted B-factors shown in Fig. 1 are listed in Table S1 of Supplementary
Content. The B-factor RMSDs (mean ± SE) of these proteins using both
FF12MChm and FF14SBhm ranged from 3.1 ± 0.2 to 9 ± 1 Å2 for Cα and from
7.3 ± 0.9 to 9.6 ± 0.2 Å2 for Cγ (Fig. 1). The respective PCCs were 0.62–0.87 or
0.63–0.89 for the Cα B-factors of the four proteins that were predicted using
FF12MChm or FF14SBhm relative to the experimental B-factors (Fig. 1). The
PCCs of the predicted Cγ B-factors using FF12MChm or FF14SBhm were
0.41–0.60 or 0.46–0.56 for the four proteins, respectively (Fig. 1). The average
PCCs of the predicted B-factors using FF12MC and FF14SB were 0.75 and 0.74
for Cα and 0.50 and 0.52 for Cγ, respectively. These results suggest that combining
the sampling of the atomic positional fluctuations over the ∼50-pssmt timescale
with the sampling of such fluctuations over conformations derived from 20 distinct
∼50-pssmt simulations can approximate the experimental B-factors with RMSDs of
<10 Å2 and the PCCs of 0.62–0.89 for Cα and 0.41–0.60 for Cγ.
4.2. Using multiple distinct initial conformations to improve
B-factor prediction
In the above B-factor calculations, the conformational disorders of a protein crystal
structure were represented by the conformational variations that resulted from 20
Article No~e00161
11 http://dx.doi.org/10.1016/j.heliyon.2016.e00161
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Table 4. Effects of the initial high-mass simulation conformation on the root mean
square deviations between experimental and calculated B-factors of GB3, BPTI,
ubiquitin, and lysozyme.
Protein
(Temperature)
Time
(pssmt)
RMSD (mean ± SE in Å2)
IC = X-ray IC at 316 nssmt IC at 632 nssmt IC at 948 nssmt
GB3 (297 K) Cα
25 3.7 ± 0.1 3.2 ± 0.2 3.3 ± 0.2 3.3 ± 0.2
50 3.1 ± 0.2 3.0 ± 0.4 2.9 ± 0.2 3.1 ± 0.4
100 3.7 ± 0.7 3.8 ± 0.8 2.9 ± 0.4 3.4 ± 0.4
Cγ
25 9.3 ± 0.5 8.8 ± 0.6 8.3 ± 0.5 8.8 ± 0.6
50 9.2 ± 0.8 10 ± 1 8.5 ± 0.6 9 ± 1
100 12 ± 2 13 ± 2 11 ± 1 12 ± 1
Ubiquitin (297 K) Cα
25 6.2 ± 0.3 6.9 ± 0.6 6.6 ± 0.4 6.3 ± 0.5
50 9 ± 1 7 ± 1 6.1 ± 0.8 6.4 ± 0.9
100 16 ± 2 9 ± 2 9 ± 1 9 ± 1
Cγ
25 7.0 ± 0.9 8.2 ± 0.5 7.9 ± 0.6 8.1 ± 0.6
50 7.3 ± 0.9 8 ± 1 7 ± 1 9 ± 1
100 12 ± 1 9 ± 2 9 ± 2 10 ± 1
BPTI (297 K) Cα
25 5.9 ± 0.3 7.1 ± 0.2 6.9 ± 0.2 6.4 ± 0.3
50 4.8 ± 0.6 6.0 ± 0.3 6.0 ± 0.3 5.2 ± 0.5
100 5.2 ± 0.8 4.9 ± 0.5 4.7 ± 0.8 4.6 ± 0.9
Cγ
25 8.6 ± 0.4 9.4 ± 0.6 9.0 ± 0.5 8.3 ± 0.6
50 8.7 ± 0.6 9.2 ± 0.9 9.4 ± 0.8 9 ± 1
100 11 ± 1 10 ± 1 11 ± 1 10 ± 1
Lysozyme (295 K) Cα
25 5.2 ± 0.3 5.8 ± 0.2 5.8 ± 0.3 5.5 ± 0.3
50 4.2 ± 0.4 5.1 ± 0.4 5.2 ± 0.7 4.7 ± 0.9
100 3.5 ± 0.6 4.8 ± 0.7 6 ± 1 6 ± 2
Cγ
25 7.4 ± 0.5 7.9 ± 0.7 7.7 ± 0.8 7.9 ± 0.7
50 7.7 ± 0.8 8 ± 1 9 ± 1 10 ± 1
100 10 ± 1 10 ± 1 12 ± 2 14 ± 3
Time: the duration of 20 distinct, independent, unrestricted, unbiased, isobaric–isothermal, and high-
mass molecular dynamics simulations using FF12MChm over which the B-factors were calculated. IC:
the initial conformation of a high-mass simulation that was taken either from an X-ray crystal structure
or from an instantaneous conformation saved at 316 nssmt, 632 nssmt, or 948 nssmt of a low-mass
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high-mass simulations of a protein. Specifically, each of the 20 simulations was
performed with a unique seed number for initial velocities and a common initial
conformation that was taken from the protein crystal structure and sequentially for
(i) 30 pssmt to set the system temperature to a desired value, (ii) 100 pssmt to
equilibrate the system at the desired temperature, and (iii) 25, 50, or up to 20,000
pssmt to sample the atomic positional fluctuations of the protein. It was not
unreasonable to suspect that the conformational heterogeneity that resulted from
the heating and equilibration over a combined period of 130 pssmt of the 20 high-
mass simulations might be insufficient to represent the conformational disorders of
the protein crystal structure.
Therefore, 20 948-nssmt low-mass MD simulations using FF12MC were carried out
for each of the four proteins to obtain protein conformations that differed from the
crystallographically determined conformation. FF12MC was used in the low-mass
simulations because it could autonomously fold Ac-(AAQAA)3-NH2 [68],
chignolin [69], and CLN025 [70] in 20 NPT MD simulations 2–6 times faster
than FF14SB, suggesting that it has a higher configurational sampling efficiency
than FF14SB [42]. In each of the 20 948-nssmt low-mass simulations for each of
the four proteins, a unique seed number was used for initial velocities, and the
crystallographically determined protein conformation was used as the initial
conformation of the 20 low-mass simulations. For each protein, three instantaneous
conformations were saved at 316-nssmt intervals of each of the 20 low-mass
simulations, resulting in three sets of 20 distinct instantaneous conformations saved
at 316 nssmt, 632 nssmt, and 948 nssmt. The 20 50-pssmt high-mass NPT MD
simulations using FF12MChm described in Section 4.1 were then repeated three
times under the same simulation conditions except that the initial conformations of
the 20 high-mass simulations were taken from those in one of the three sets of 20
distinct instantaneous conformations.
As listed in Table 4, the differences among the B-factor RMSDs derived from
using the conformations saved at 316 nssmt, 632 nssmt, and 948 nssmt were
marginal. Of these RMSDs, most of the RMSDs on the 50-pssmt timescale are
smaller than those on a shorter or longer timescale (Table 4), which is consistent
with the observation described in Section 4.1. For each of the four proteins, there
was a significant difference in RMSD between the B-factors derived from using
the conformations of the 20 low-mass simulations and those derived from using the
respective crystal structure conformation (Table 4). For BPTI and lysozyme, the
RMSDs derived on the 50-pssmt timescale from the conformations of the low-mass
molecular dynamics simulation of the respective crystal structure using FF12MC. RMSD: root mean
square deviation. SE: standard error calculated from 20 distinct, independent, unrestricted, unbiased,
isobaric–isothermal, and high-mass molecular dynamics simulations using FF12MChm.
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simulations were larger than those from the respective crystal structure, and the
difference (mean ± SE) was ≤2.3 ± 0.6 Å2 (Table 4). For GB3 and ubiquitin, the
reverse was observed, and the difference (mean ± SE) was ≤2.9 ± 0.6 Å2
(Table 4). These results suggest that the use of varied conformations from the
crystal structure conformation that are sampled in 20 948-nssmt low-mass
simulations may slightly improve the B-factor prediction for proteins that are
devoid of disulfide bonds but slightly impair the prediction for proteins with their
conformations restrained by disulfide bonds.
4.3. Twenty ∼50-pssmt simulations might be conducive to
prediction of B-factors
The present study demonstrates that the atomic positional fluctuations of a folded
globular protein sampled over a timescale of ∼50 pssmt of 20 high-mass MD
simulations can approximate the experimental B-factors better than the fluctuations
sampled over a shorter or longer timescale. This observation is in agreement with a
recent report showing that the experimental Cα and Cγ B-factors of GB3, BPTI,
ubiquitin, and lysozyme could be best reproduced with the standard-mass NPT MD
simulations with Δt = 0.10 fssmt on the timescale of 50 pssmt [42]. According to the
mass scaling theory for time compression and expansion in MD simulation
described in Section 2, the standard-mass simulation with Δt = 0.10 fssmt is
equivalent to the high-mass simulation with Δt = 1.00 fssmt. Indeed, the Cα and Cγ
B-factor RMSDs of all four proteins on the 50 pssmt timescale in Table 2 are nearly
identical to the corresponding ones in Table S14 of Ref. [42]. Further, the present
finding that sampling over 50 pssmt in 20 high-mass MD simulations best
reproduces the experimental B-factors is consistent with the report that the internal
motions are on the order of tens or hundreds of pssmt [67]. It is also consistent with
the report that the experimental Lipari-Szabo order parameters [71] of backbone
N–H bonds of the four proteins were best reproduced with NPT MD simulations
using FF12MC on the timescale of 50 pssmt [42]. These consistent results suggest
that through performing multiple picosecond high-mass NPT MD simulations one
could capture the true thermal motions of folded globular proteins that are reflected
in B-factors and the Lipari-Szabo order parameters.
This study compared two simulation conditions for B-factor prediction. One used
the conformational heterogeneity resulting from the heating and equilibration of a
respective crystal structure over a combined period of 130 pssmt of 20 high-mass
MD simulations. The other used the conformational heterogeneity resulting from
the heating and equilibration of multiple distinct instantaneous conformations,
which were taken from 20 948-nssmt low-mass MD simulations of the respective
crystal structure, over a combined period of 130 pssmt of 20 high-mass MD
simulations. The result of this comparative study shows that sampling the atomic
positional fluctuations of the simulations using multiple distinct instantaneous
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conformations approximates the experimental B-factors of GB3 and ubiquitin
better than sampling the fluctuations of the simulations using a crystal structure
conformation and vice versa for BPTI and lysozyme. This observation correlates
well with the structures of the four proteins. Unlike BPTI and lysozyme, GB3 and
ubiquitin do not have any disulfide bonds to restrain their folded conformations.
There is no structural difference between the solution and solid states for GB3 or
ubiquitin [54, 56, 72, 73]. However, the C14–C38 disulfide bond in BPTI flips
between left- and right-handed configurations [74] in the NMR structure (PDB ID:
1PIT) [75]. This bond is locked at the right-handed configuration in the crystal
structure (PDB ID: 4PTI) [55]. For lysozyme, its C64–C80 disulfide bond adopts
both configurations in the NMR structure (PDB ID: 1E8L) [76] and the right-
handed configuration in the crystal structure (PDB ID: 4LZT) [57]. As reported
recently in Ref. [42], sampling the conformation of BPTI in solution using
FF12MC for 3.16 nssmt captured both left- and right-handed configurations of
C14–C38, but the left-handed configuration is absent at the crystalline state. This
explains why sampling the atomic positional fluctuations over multiple distinct
instantaneous conformations in solution impaired the B-factors of BPTI and
lysozyme, but improved those of GB3 and ubiquitin. This also helps clarify why
the B-factor RMSDs predicted using FF12MC progressed in time (Table 2) and
underscores the necessity to confine the sampling to the timescale of ∼50 pssmt.
In this study, the average PCCs of the predicted Cα B-factors using FF12MC and
FF14SB relative to the experimental values are 0.75 and 0.74, respectively, while
the individual PCCs of the predicted Cα B-factors for lysozyme using FF12MC
and FF14SB are 0.79 and 0.71, respectively. To date, the best reported average
PCC of the predicted Cα B-factors using a statistical method is 0.61 [46]; the best
reported individual PCC of the predicted Cα B-factors of lysozyme using a single-
parameter harmonic potential is 0.71 [47]. These coefficients suggest that the
physics-based method that uses multiple ∼50-pssmt NPT MD simulations with
FF12MC or FF14SB to predict Cα B-factors may be as good as if not better than
the knowledge-based methods that use statistics or single-parameter harmonic
potentials to predict Cα B-factors. Further, according to a survey of ∼900 amino
acids in four protein crystal structures with resolutions of 1.60–1.70 Å, the 95%
confidence interval for the experimental B-factors derived by the refinement
procedure is mean ± ∼9.8 Å2 [8]. The present study shows that the upper limit of
the RMSDs between 556 calculated Cα and Cγ B-factors (Table S1 of
Supplementary Content) and the corresponding experimental B-factors of GB3,
ubiquitin, BPTI, and lysozyme with resolutions of 0.95–1.80 Å is 9.6 Å2 (Table 2).
This limit indicates that the Cα and Cγ B-factors of the four proteins predicted
from 20 50-pssmt high-mass simulations using FF12MC or FF14SB are accurate
because these predicted B-factors are within the 95% confidence interval of the
experimental B-factors.
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While further studies are needed, the present work suggests that sampling the
atomic positional fluctuations in 20 distinct, independent, unrestricted, unbiased,
∼50-pssmt, and high-mass classical NPT MD simulations may be a feasible MD
simulation procedure of a physics-based method to accurately predict B-factors of
a folded globular protein. These high-mass simulations may be performed with 20
distinct, initial conformations taken from the last instantaneous conformations of
20 distinct, independent, unrestricted, unbiased, 316-nssmt, and low-mass classical
NPT MD simulations of a comparative model of the globular protein to
prospectively predict main-chain and side-chain B-factors for target-structure-
–based drug design. These high-mass simulations may also be performed with a
common initial conformation taken from a crystal structure to retrospectively
predict B-factors for insights into relative contributions of the thermal motions in
time and the conformational and static lattice disorders in space to the experimental
B-factors.
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